2024年湖南某医院哌拉西林他唑巴坦临床应用分析

参考文献[1]李星洁,范亚新,赵锦锦,等.哌拉西林-他唑巴坦相关肾毒性的研究进展[J].中国感染与化疗杂志,2022,22(2):235-240.[2]雷海波,刘湘.哌拉西林他唑巴坦致药物超敏反应综合征1例[J].中南药学,2021,19(08):1748-1750.[3]郑芳芳.哌拉西林钠他唑巴坦钠致不良反应23例分析[J].中国乡村医药,2022,29(05):52-53.[4]井军虎.哌拉西林他唑巴坦致重度血小板减少1例[J].中国新药与临床杂志,2022,41(05):315-316.[5]梁万年,廖志远,钟超,等.哌拉西林他唑巴坦致血小板减少1例并个案文献分析[J].中国药业,2023,32(10):120-123.[6]姬波,李树蕤,关月,等.头孢哌酮钠舒巴坦钠与哌拉西林钠/他唑巴坦钠治疗复杂性尿路感染的安全性与有效性[J].中华医院感染学杂志,2024,34(06):841-846.[7]孙宁,赵春阳,蔡佳怡,等.不同配比哌拉西林钠他唑巴坦钠在重症肺炎治疗中的安全性及影响因素研究[J].中国医院用药评价与分析,2024,24(02):202-206.[8]贺辉.哌拉西林他唑巴坦治疗COPD急性发作期的临床效果[J].临床合理用药,2023,16(34):46-49.[9]王宗孝,郑志强,罗娓娓,等.我院住院患者哌拉西林他唑巴坦的应用分析[J].临床合理用药杂志,2021,14(10):4-6.[10]彭昊.哌拉西林/他唑巴坦治疗泌尿系统感染的疗效分析[J].医药前沿,2021,11(05):102-103.[11]武裕兴.哌拉西林钠他唑巴坦在重症脓毒症治疗中的临床效果分析[J].现代医学与健康研究电子杂志,2023,7(11):1-3.[12]张传洲,陈杰,赵俊,等.注射用哌拉西林钠他唑巴坦钠致产妇过敏性休克1例[J].中国药业,2020,29(11):95-96.[13]刘辉.哌拉西林他唑巴坦治疗小儿重症肺炎的效果观察[J].保健医学研究与实践,2022,19(11):70-73.[14]张婷婷.惠民医保使群众看病有“医”靠[J].新湘评论,2024,(04):28.[15]詹煦旭,任志强,刘英,等.哌拉西林他唑巴坦钠致血小板减少症1例药学监护[J].临床合理用药,2023,16(36):156-158.[16]HeC,LingS,JinY,etal.Simultaneousdeterminationofpiperacillin,metronidazole,andtazobactaminplasmabyUPLC-MS/MSandapplicationtoapharmacokineticstudyinpediatriclivertransplantpatients.JChromatogrBAnalytTechnolBiomedLifeSci.2025;1258:124605.[17]FarukDemirocak,DianaLangerak,ErlanggaYusuf.ReliabilityofvariousAntimicrobialSusceptibilityTestingMethodsforPiperacillin/tazobactaminchallengingEscherichiacoliisolates.[J].Journalofglobalantimicrobialresistance,2025,41:211-215.[18]JARoberts,AJHeffernan,MGChai,PNAHarris,ALegg,AFarkas,KLaupland,JDhanani,CFourie,LMurray,HAbdulAziz,JUngerer,BMcWhinney,JLipman,MOCotta.ResistanceOptimisedAntibioticDosing(TheROADStudy):Isdosingofmeropenemandpiperacillin-tazobactamoptimisedtopreventtheemergenceofantibioticresistancesafeandfeasibleintheICU?Apilotstudy[J].CMICommunications,2025,2(1):105051-105051.[19]BhimBahadurChaudhari,JayaShreeDilliBatcha,ArunPrasathRaju,SaikumarMatcha,LeslieELewis,SudheerMoorkoth,SurulivelrajanMallayasamy.AssessmentofPiperacillin-TazobactamPopulationPharmacokineticModelsinNeonates:AnExternalValidation.[J].EuropeanJournalofdrugmetabolismandpharmacokinetics,2024,50(1):1-9.[20]PaulWhitaker,AndrewGibson,JohnFarrell,LindseyGillgrass,XiaoliMeng,DanielPeckham,DeanJNaisbitt.Prospectivepiperacillinlymphocytetransformationtestinginpatientswithcysticfibrosisreceivingregularandde